ATOSSA THERAPEUTICS, INC. — Director's Dealing 2013

Oct 4, 2013

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2013-10-01

Reporting Person: Chen Shu-Chih (Director, Chief Scientific Officer, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2013-10-01	Common Stock	S	7265	$5.658	Disposed	4268315	Indirect

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a trading plan previously adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The trading plan was previously reviewed and approved by the Company's board of directors in accordance with Rule 10b5-1.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.57 to $5.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F3: Ensisheim Partners, LLC is wholly owned by the Reporting Person and Dr. Steven Quay, the Chief Executive Officer of the Company. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of all such securities for purposes of Section 16 or any other purpose.